Physician profile
Rubin Lin
NPI 1679678916
$1,177.56
in general payments reported to CMS, 2019-2025
10 companies · $1,002 in 2025
The $1,002 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $40.33 · 2023: $37.69 · 2024: $97.72 · 2025: $1,002.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $880 · Food and Beverage: $257.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $880.00 |
| Food and Beverage | $257.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $730.00 | 2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $150.00 | 2025 | |
| Exact Sciences Corporation | $121.82 | 2025 | The Cologuard Plus Collection Kit |
| Hologic Sales and Service, LLC | $49.06 | 2024 | Aptima, Thinprep 2000 Processor |
| Sanofi Pasteur INC. | $24.67 | 2024 | |
| Alk-Abello, INC | $23.99 | 2024 | Grastek, Ragwitek, Odactra |
| Novo Nordisk INC | $23.56 | 2023 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $21.00 | 2022 | |
| Glaxosmithkline, LLC. | $19.33 | 2022 | |
| Cranial Technologies, INC | $14.13 | 2023 | Doc Band |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rubin Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.